GeneTex
United States (US)

PUMA peptide

Cat No. GTX29644

Application Blocking
Species Human
APPLICATION

Application Note

The peptide is used for blocking the activity of anit-PUMA antibody (GTX29643). Incubatingthe peptide with equal volume of antibody for 30 min at 37ºC usually completely blocks theactivity of anti-PUMA in Western blotting.
PROPERTIES

Form

Liquid

Buffer

PBS pH7.2 with 10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl, 0.1% bovine serum albumin, and 0.02% sodium azide

Storage

Store the peptide at -20˚C, stable for one year.

Concentration

0.20 mg/ml (Please refer to the vial label for the specific concentration.)

Conjugation

Unconjugated

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

Bcl2 Binding Component 3,Jfy-1,Jfy1,Puma,Bbc3

Background

Apoptosis is related to many diseases and development. The p53 tumor-suppressor protein induces apoptosis through transcriptional activation of several genes. A novel p53 inducible pro-apoptotic gene was identified recently and designated PUMA (for p53 upregulated modulator of apoptosis) and bbc3 (for Bcl-2 binding component 3) in human and mouse (1-3). PUMA/bbc3 is one of the pro-apoptotic Bcl-2 family members including Bax and Noxa, which are also transcriptional targets of p53. The PUMA gene encodes two BH3 domain-containing proteins termed PUMA-a and PUMA-b (1). PUMA proteins bind Bcl-2, localize to the mitochondria, and induce cytochrome c release and apoptosis in response to p53. PUMA may be a direct mediator of p53-induced apoptosis.

Research Area

Package List Price ($)
$ 179